News Image

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Provided By GlobeNewswire

Last update: Feb 2, 2024

Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study

Read more at globenewswire.com

SYNLOGIC INC

NASDAQ:SYBX (8/22/2025, 8:00:00 PM)

1.46

+0.06 (+4.29%)



Find more stocks in the Stock Screener

Follow ChartMill for more